Obesity And Saxenda® Knowledge Checks - I

1. Weight gain occurs when energy intake exceeds energy expenditure

True

False

Obesity is a result of an energy imbalance

Explanation

Obesity is a result of an energy imbalance

2. Saxenda® is the only GLP-1 agonist approved for Weight reduction, it had approvals from ……

FDA

EMA

Iraq MOH

All the above

Saxenda^® has FDA, EMA and Iraq MOH approvals and it’s approved as an adjunct to a reduced- calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI of ≥30 kg/m²) or who are overweight (BMI of ≥27 kg/m²) in the presence of at least one weight-related comorbid condition.

Explanation

Saxenda^® has FDA, EMA and Iraq MOH approvals and it’s approved as an adjunct to a reduced- calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI of ≥30 kg/m²) or who are overweight (BMI of ≥27 kg/m²) in the presence of at least one weight-related comorbid condition.

3. Every 1 Kg gain in Weight is associated with ……… increase in risk of diabetes.

3%

6%

9%

12%

In an 8 years study in the US, for every Kg increase in self-reported weight, diabetes increased by 9% (Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, et al. Diabetes trends in the U.S, Diabetes Care. 2000 Sep;23(9):1278-83.).

Explanation

In an 8 years study in the US, for every Kg increase in self-reported weight, diabetes increased by 9% (Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, et al. Diabetes trends in the U.S, Diabetes Care. 2000 Sep;23(9):1278-83.).

4. During the SCALE program, Saxenda® was found to reduce the followings

Lipid Profile

Systolic Blood Pressure

Glucose Level

Weight

This result was proven in the phase 3 trials for Saxenda®(SCALE studyle Roux et al. Lancet. 2017 Apr 08;389(10077):1399-409.)

Explanation

This result was proven in the phase 3 trials for Saxenda®(SCALE studyle Roux et al. Lancet. 2017 Apr 08;389(10077):1399-409.)

Submit

5. In a 3 years clinical trial, losing weight with Saxenda®, delays the onset of T2DM by ......

60%

70%

80%

90%

Losing weight with Saxenda®, delays the onset of T2DM in by 80%, This result was proven in the phase 3 trials for Saxenda® (SCALE studyPi-Sunyer et al. N Engl J Med. 2015;373(1):11-22.)

Explanation

Losing weight with Saxenda®, delays the onset of T2DM in by 80%, This result was proven in the phase 3 trials for Saxenda® (SCALE studyPi-Sunyer et al. N Engl J Med. 2015;373(1):11-22.)

6. Which international agencies Considered obesity as a global health challenge requiring a "chronic disease management model" ?

World Health Organization (WHO)

European Medicines Agency
(EMA)

American Medical Association(AMA)

Canadian Medical Association(CMA)

The Obesity Society
(TOS)

The WHO has declared obesity as a disease in 2000, and other agencies reached the same decision afterward

Explanation

The WHO has declared obesity as a disease in 2000, and other agencies reached the same decision afterward

Submit